Haemonetics Corp. (HAE) Misses Q2 EPS Views; Guides Soft FY11 EPS
Tweet
Share
E-mailGet Alerts HAE Hot Sheet
Price: $102.92 +0.07%
EPS Growth %: 0.0%
Financial Fact:
Net income: 0.39
Today's EPS Names:
VIVO, BIOX, PMCB, More
EPS Growth %: 0.0%
Financial Fact:
Net income: 0.39
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Haemonetics Corp. (NYSE: HAE) reported Q2 EPS of $0.72, $0.76 worse than the analyst estimate of $0.76. Revenue for the quarter came in at $179.4 million versus the consensus estimate of $173.55 million.
Haemonetics Corp. sees FY2011 EPS of $3.00-$3.10, versus the consensus of $3.38.
Haemonetics Corp. sees FY2011 EPS of $3.00-$3.10, versus the consensus of $3.38.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ambarella (AMBA) Tops Q2 EPS by 1c; offers guidance
- Oxford Industries (OXM) Tops Q2 EPS by 4c; offers guidance
- lululemon athletica (LULU) Tops Q2 EPS by $1.10, Cuts Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
